---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087269"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:36:09.454667+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q2 net loss $38.5M; JNJ-2113 advances to Phase 3 in psoriasis

## Summary
- Net loss of $38.5M ($0.68/share) in Q2 2023 vs $41M loss in Q2 2022; cash $313.4M at June 30.
- JNJ-2113 Phase 2b FRONTIER 1 met all endpoints; 78.6% PASI 75 at 100mg BID; moving to Phase 3 psoriasis and Phase 2b UC.
- Rusfertide Phase 2 REVIVE positive results presented at EHA2023; Phase 3 VERIFY enrollment continues targeting Q1 2024 completion.
- Completed $115M equity financing in April 2023.
- License revenue $0 vs $0.9M in Q2 2022 as prior period included $25M milestone.

## SEC filing metadata
- accession: 0001104659-23-087269
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465923087269/0001104659-23-087269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465923087269/tm2322752d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087269
- JSON: https://secwatch.observer/filing/0001104659-23-087269.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087269.txt

## Key facts
- Earnings Releases
  Protagonist Therapeutics, Inc reported the second quarter ended June 30, 2023 results: revenue zero, net income Net loss was $38.5 million, or $0.68 per share, for the three months ended June 30, 2023, EPS $0.68 per share.
  - Period: the second quarter ended June 30, 2023
  - Revenue: zero
  - Net income: Net loss was $38.5 million, or $0.68 per share, for the three months ended June 30, 2023
  - EPS: $0.68 per share
  - Result: reported results
  source text: On August 3, 2023, Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923087269/0001104659-23-087269-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.